AFP and neoplasm: Serum AFP dynamics and composite tumour markers refine candidacy: US allocation policy withholds an automatic exception when AFP > 1000 ng/mL unless it can be reduced and sustained < 500 ng/mL, reflecting aggressive biology and a higher risk of wait-list drop-out.